Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine dose comparison versus hydroxyurea in myeloproliferative neoplasms with increased MDSCs
ChiCTR2200065969Phase 3Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Dec 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of decitabine and hydroxyurea in myeloproliferative disorder (MPD) (3 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Number of MDSCs and related biological activity indexes, Objective response rate and 3 more. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
decitabinehydroxyurea
03
Conditions
myeloproliferative disorder (MPD)
Beyond the preview
Go deeper on ChiCTR2200065969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065969.